bioAffinity Technologies, Inc. - Common Stock (BIAF)
0.2920
-0.0750 (-20.44%)
bioAffinity Technologies, Inc. is a biotechnology company focused on developing innovative diagnostic and therapeutic solutions for the early detection and treatment of cancer
The company leverages its proprietary technologies to create advanced cellular and molecular products aimed at improving patient outcomes, particularly in areas where traditional methods fall short. By harnessing the power of biological mechanisms, bioAffinity seeks to provide healthcare professionals with novel tools for identifying cancer at its earliest stages and tailoring personalized treatment plans for patients.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Via Chartmill · March 17, 2025

Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · March 17, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · March 17, 2025

Via Benzinga · November 1, 2024

Via Benzinga · October 23, 2024

Via Benzinga · October 18, 2024

It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label.
Via Talk Markets · October 9, 2024

bioAffinity Technologies just reported results for the second quarter of 2024.
Via InvestorPlace · August 14, 2024

bioAffinity Technologies just reported results for the first quarter of 2024.
Via InvestorPlace · May 15, 2024

bioAffinity Technologies just reported results for the fourth quarter of 2023.
Via InvestorPlace · April 1, 2024

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.20% to 38,662.69 while the NASDAQ rose 0.64% to 16,041.08. The S&P 500 also rose, gaining, 0.53% to 5,105.72.
Via Benzinga · March 6, 2024

Shares of Mesoblast Limited (NASDAQMESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.
Via Benzinga · March 11, 2024

Via Benzinga · March 6, 2024

BioAffinity Technologies shares are trading lower by 50.7% during Wednesday's session. The company announced a securities purchase agreement with institutional investors.
Via Benzinga · March 6, 2024

Shares of United Natural Foods, Inc. (NYSEUNFI) fell sharply during Wednesday’s session following second-quarter results.
Via Benzinga · March 6, 2024

Shares of Compugen Ltd. (NASDAQCGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program. Compugen shares jumped 204.1% to $2.22 on Tuesday.
Via Benzinga · December 19, 2023

Shares of SOPHiA GENETICS SA (NASDAQSOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
Via Benzinga · March 5, 2024

Via Benzinga · November 30, 2023

Gainers Gaucho Group Holdings, Inc. (NASDAQVINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2 million and $0.7 million respectively.
Via Benzinga · October 4, 2023